13F Holdings
中文EN

LH LABCORP HOLDINGS INC.

Services-Medical Laboratories · NYSE · SEC CIK 920148 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.0%
TTM net income YoY17.4%
TTM EPS YoY19.7%
Revenue 3-yr CAGR6.6%
Net income 3-yr CAGR14.9%

Margins

Gross margin29.0%
Operating margin10.3%
Net margin6.9%
FCF margin8.8%
EBITDA margin15.1%

Returns

ROE11.4%
ROA5.4%
ROIC (approx.)8.6%
Asset turnover0.78x

Leverage & solvency

Liabilities / assets53.2%
Debt / equity0.66x
Current ratio1.41x
Interest coverage6.52x

Cash quality & payout

Operating cash flow / net income1.81x
Accruals ratio-4.4%
Payout ratio23.6%
Capex / revenue3.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20212022-12-31FY20212021-12-31
Income statement
Revenue$13.95B$13.01B$12.16B$11.86B$13.14B
Cost of revenue$9.94B$9.38B$8.80B$8.15B$8.14B
Gross profit$4.01B$3.62B$3.36B$3.71B$4.99B
SG&A expense$2.22B$2.23B$2.02B$1.76B$1.69B
Operating income$1.38B$1.09B$725.60M$1.44B$3.05B
Interest expense$224.10M$208.30M$199.60M$179.80M$211.80M
Pretax income$728.90M$629.70M$504.00M$1.10B$2.46B
Income tax$229.80M$212.40M$188.50M$233.90M$690.00M
Net income$876.50M$746.00M$418.00M$1.28B$2.38B
EBITDA$2.07B$1.73B$1.30B$1.97B$3.63B
EPS (basic)10.548.894.8014.0524.60
EPS (diluted)10.468.844.7713.9724.39
Dividends declared per share2.882.882.882.16—
Weighted avg. shares (diluted)83.80M84.40M87.60M91.60M97.50M
Balance sheet
Cash & equivalents$532.30M$1.52B$536.80M$320.60M$1.38B
Receivables$2.10B$1.94B$1.91B$1.79B$2.26B
Inventory$534.70M$493.20M$474.60M$470.60M$401.40M
Current assets$4.02B$4.81B$3.77B$4.62B$5.33B
PP&E, net$3.08B$3.05B$2.91B$2.79B$2.82B
Goodwill$6.79B$6.37B$6.14B$6.12B$5.89B
Intangibles$3.60B$3.49B$3.34B$3.12B$3.74B
Total assets$18.39B$18.38B$16.73B$20.16B$20.39B
Current liabilities$2.82B$3.33B$3.23B$3.08B$2.78B
Short-term debt$500.10M$1.00B$999.80M$301.30M$1.50M
Long-term debt$5.08B$5.33B$4.05B$5.04B$5.42B
Total debt$5.58B$6.33B$5.05B$5.34B$5.42B
Total liabilities$9.76B$10.31B$8.83B$10.04B$10.09B
Shareholders' equity$8.62B$8.05B$7.88B$10.10B$10.27B
Net debt$5.05B$4.81B$4.52B$5.02B$4.04B
Shares outstanding82.20M83.40M83.90M88.20M93.10M
Cash flow statement
Operating cash flow$1.64B$1.59B$1.33B$1.96B$3.11B
Capital expenditure$434.50M$489.90M$453.60M$429.30M$421.50M
Free cash flow$1.21B$1.10B$874.10M$1.53B$2.69B
Investing cash flow-$1.19B-$1.37B-$1.17B-$1.65B-$884.60M
Financing cash flow-$1.46B$779.90M-$59.30M-$1.32B-$2.07B
Depreciation & amortization$681.10M$643.50M$577.30M$537.20M$577.00M
Stock-based compensation$125.80M$116.70M$128.70M$116.80M$132.90M
Dividends paid$240.70M$243.10M$254.00M$195.20M—
Share buybacks$450.00M$250.10M$1.00B$1.10B$1.67B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.